New Delhi Jan 9 (PTI) Drug firm Zydus Cadila today said it has received approval from the US health regulator to sell Sirolimus Tablets used to prevent rejection in organ transplantation in the American market with 180 days of marketing exclusivity.Zydus Cadila received the final approval from the US Food and Drug Administration (USFDA) to market Sirolimus tablets 0.5 mg with 180 days of marketing exclusivity the company said in a statement.The Ahmedabad-based firm has also received USFDA approval to market Duloxetine delayed release capsules in different strengths of 20 mg 30 mg and 60 mg it added.As per the IMS
